Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Kerr

Showing results (471-480 of 475) with videos related to

Pageof 48
Sort By:
You have reached the last page of results.This site can display upto 475 results.
Gynecologic Oncology|May 4, 2023
Detection of endometrial cancer using tampon-based collection and methylated DNA markersJamie N Bakkum-Gamez, Mark E Sherman, Seth W Slettedahl, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 2, 2017
Molecular testing for the clinical diagnosis of fibrolamellar carcinomaRondell P Graham, Matthew M Yeh, Dora Lam-Himlin, et al.
Gynecologic Oncology|April 4, 2022
Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibilityLisa M Marinelli, John B Kisiel, Seth W Slettedahl, et al.
Oncotarget|April 21, 2017
Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to deliveryAlan H Bryce, Jan B Egan, Mitesh J Borad, et al.
JCO Precision Oncology|February 15, 2019
Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in CholangiocarcinomaJan B Egan, David L Marks, Tara L Hogenson, et al.
Pageof 48

Showing results (471-480 of 475) with videos related to

Sort By:
Pageof 48
You have reached the last page of results.This site can display upto 475 results.
Gynecologic Oncology|May 4, 2023
Detection of endometrial cancer using tampon-based collection and methylated DNA markersJamie N Bakkum-Gamez, Mark E Sherman, Seth W Slettedahl, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 2, 2017
Molecular testing for the clinical diagnosis of fibrolamellar carcinomaRondell P Graham, Matthew M Yeh, Dora Lam-Himlin, et al.
Gynecologic Oncology|April 4, 2022
Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibilityLisa M Marinelli, John B Kisiel, Seth W Slettedahl, et al.
Oncotarget|April 21, 2017
Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to deliveryAlan H Bryce, Jan B Egan, Mitesh J Borad, et al.
JCO Precision Oncology|February 15, 2019
Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in CholangiocarcinomaJan B Egan, David L Marks, Tara L Hogenson, et al.
Pageof 48